减重降糖药取代抗癌药登顶,已成定局文 | 王莉萍凌馨编 |王小图/视觉中国全球两大跨国药企诺和诺德和默沙东在2026年2月初,相继发布2025年财报。没有悬念,诺和诺德的司美格鲁肽,全球销售额已超越默沙东的Keytruda(帕博利珠单抗,下称“K药”)。自2023年默沙东的K药以250亿美元取代蝉联全球药王12年之久的自免药物修美乐(阿达木单抗),将抗肿瘤PD-1药物的市场竞争格局推向高潮,到...
Source Link减重降糖药取代抗癌药登顶,已成定局文 | 王莉萍凌馨编 |王小图/视觉中国全球两大跨国药企诺和诺德和默沙东在2026年2月初,相继发布2025年财报。没有悬念,诺和诺德的司美格鲁肽,全球销售额已超越默沙东的Keytruda(帕博利珠单抗,下称“K药”)。自2023年默沙东的K药以250亿美元取代蝉联全球药王12年之久的自免药物修美乐(阿达木单抗),将抗肿瘤PD-1药物的市场竞争格局推向高潮,到...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.